What is a RASP inhibitor? A novel approach to fighting inflammation
•
4 min read
According to Aldeyra Therapeutics, dry eye disease affects approximately 34 million or more adults in the United States, and RASP inhibitors represent a new frontier in addressing the inflammatory component of conditions like this. They offer a novel and highly targeted mechanism of action compared to older anti-inflammatory drugs.
